The overall objective of the current SCOR and the PROPOSED RENEWAL is to elucidate the molecular basis for the long-term adaptive response of the heart to injury, both inherited and acquired, whether manifested by hypertrophy or dilitation. In Project 3 we focus on the paradigm of dilated cardiomyopathy with arrhythmias affecting primarily the right ventricle. Arrhythmogenic right ventricular dysplasia (ARVD), is a familial cardiomyopathy of unknown etiology characterized by a gradual loss of myocytes and replacement by fatty and fibrous tissue which, as it progresses, leads to dilitation of the right ventricle and impaired cardiac function. Thus, ARVD is initiated in the right ventricle in contrast to FDCM which is initiated in the left ventricle. The pathology of ARVD extends from the right ventricle to involve the left ventricle which is a mirror image to both the initial site of involvement and the spread of pathology observed in FDCM. The clinical course is characterized by arrhythmias, sudden death, and heart failure, process whereby myocardial cells die and are replaced by fatty-fibrous tissue is due to apoptosis Although four genetic loci are associated with this disease, none of the causative genes have been identified. We propose to identify the gene responsible for ARVD in our family which we recently mapped to a novel loci, 3p23, using either a positional candidate or positional cloning approach. We will use physical mapping information available on the World Wide Web to identify YAC clones and ESTs which map to the critical regions. We will use this cloned material to identify new genetic markers to further delineate the region as well as new candidate genes to be sequenced in our families. We further propose to map a novel locus in a family we have identified that is not linked to any known ARVD locus and ultimately to identify that gene as well. These objectives address the general hypothesis that identifying genetic defects and unraveling the molecular basis for familial cardiomyopathies will provide insight fundamental to the understanding of ventricular failure observed in response to a variety of other familial and acquired diseases. Additionally, unraveling the chamber specific stimuli or gene that localizes and determines the ventricular response in the right as opposed to the left ventricle and elucidating the role of apoptosis in heart remodeling will have important implications for the pathogenesis and treatment of heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
2P50HL054313-06
Application #
6316437
Study Section
Special Emphasis Panel (ZHL1-CSR-Y (O1))
Project Start
1995-02-17
Project End
2005-01-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2000
Total Cost
$184,963
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Nassif, Michael E; LaRue, Shane J; Raymer, David S et al. (2016) Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. Circ Heart Fail 9:
Adamo, Luigi; Nassif, Michael; Tibrewala, Anjan et al. (2015) The Heartmate Risk Score predicts morbidity and mortality in unselected left ventricular assist device recipients and risk stratifies INTERMACS class 1 patients. JACC Heart Fail 3:283-90
Nassif, Michael E; Patel, Jayendrakumar S; Shuster, Jerrica E et al. (2015) Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. JACC Heart Fail 3:146-53
Mann, Douglas L; Mochly-Rosen, Daria (2013) Translational medicine: mitigating risks for investigators. Nat Rev Drug Discov 12:327-8
Lombardi, Raffaella; Rodriguez, Gabriela; Chen, Suet Nee et al. (2009) Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 119:1398-407
Lombardi, Raffaella; Bell, Achim; Senthil, Vinitha et al. (2008) Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res 79:109-17
Mann, Douglas L; Bozkurt, Biykem; Torre-Amione, Guillermo et al. (2008) Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin Transl Sci 1:142-5
Daw, E W; Lu, Y; Marian, A J et al. (2008) Identifying modifier loci in existing genome scan data. Ann Hum Genet 72:670-5
Marian, Ali J (2008) Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol 23:199-205
Daw, E Warwick; Chen, Suet Nee; Czernuszewicz, Grazyna et al. (2007) Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet 16:2463-71

Showing the most recent 10 out of 69 publications